NASDAQ
24.12.25 | 19:00
12,010 US-Dollar
+1,87 % +0,220
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| So | Bullish Analyst Sentiment on Fulcrum Therapeutics (FULC) Following Positive Updates from Phase 1b PIONEER Study | 3 | Insider Monkey | ||
| 11.12. | Truist Securities raises Fulcrum Therapeutics stock price target on positive sickle cell data | 1 | Investing.com | ||
| 10.12. | Fulcrum Therapeutics announces pricing of upsized $175M public offering of common stock, pre-funded warrants | 3 | Seeking Alpha | ||
| 10.12. | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants | 1 | GlobeNewswire (USA) | ||
| 08.12. | Fulcrum Therapeutics announces proposed $150.0 million public offering of common stock | 1 | Seeking Alpha | ||
| FULCRUM THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 08.12. | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 08.12. | Fulcrum Therapeutics Stock Rally Ignited By Promising Sickle Cell Results | 2 | Benzinga.com | ||
| 08.12. | Stifel raises Fulcrum Therapeutics stock price target to $25 on strong ASH data | 1 | Investing.com | ||
| 08.12. | Goldman Sachs reiterates rating on Fulcrum Therapeutics stock after positive trial data | 3 | Investing.com | ||
| 08.12. | Goldman Sachs bekräftigt Rating für Fulcrum Therapeutics nach positiven Studiendaten | 2 | Investing.com Deutsch | ||
| 08.12. | BofA Securities raises Fulcrum Therapeutics stock price target on SCD drug data | 3 | Investing.com | ||
| 08.12. | Fulcrum Therapeutics stock price target raised to $25 from $18 at H.C. Wainwright | 2 | Investing.com | ||
| 08.12. | Fulcrum Therapeutics shares rise after positive phase 1b sickle cell trial results | 4 | Seeking Alpha | ||
| 08.12. | Fulcrum Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.12. | Leerink Partners raises Fulcrum Therapeutics stock price target on strong sickle cell data | 5 | Investing.com | ||
| 08.12. | Fulcrum Therapeutics stock price target raised to $10 from $7 at RBC Capital | 1 | Investing.com | ||
| 06.12. | Fulcrum Therapeutics: Starke Studiendaten für Sichelzell-Medikament Pociredir | 4 | Investing.com Deutsch | ||
| 06.12. | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting | 117 | GlobeNewswire (Europe) | ? Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at the Week 6 timepoint (n=12): mean absolute HbF in the 20 mg cohort increased by 9.9% at... ► Artikel lesen | |
| 05.12. | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 02.12. | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025 | 1 | GlobeNewswire (USA) |
1 2 3 Weiter >>
56 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 38,985 | -0,35 % | QIAGEN N.V.: QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million | Return of approximately $500 million maximum approved by shareholders set to be completed on January 7, 2026 Capital return to be conducted through synthetic share repurchase combines a... ► Artikel lesen | |
| CUREVAC | 3,536 | +4,12 % | Curevac-Übernahme durch Biontech wird im Januar vollendet | MAINZ/TÜBINGEN (dpa-AFX) - Nach Ablauf einer weiteren Frist soll die Übernahme des Biotechnologieunternehmens Curevac durch Biontech im Januar komplett abgeschlossen werden. Zum Ende einer Nachangebotsfrist... ► Artikel lesen | |
| MODERNA | 27,250 | -0,51 % | Moderna, Inc.: CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate | Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensurePartnership strengthens global preparedness against a significant pandemic threatIf... ► Artikel lesen | |
| VALNEVA | 3,632 | +0,22 % | Abend-Update: Valneva legt kräftig zu - jetzt reden alle über diesen Wert! | ||
| AMGEN | 280,45 | -0,23 % | ROUNDUP/Aktien New York Schluss: Erholung geht weiter | NEW YORK (dpa-AFX) - Die US-Börsen haben sich am Freitag weiter von ihrem jüngsten Rücksetzer erholt. Eine Jahresendrally sei nach wie vor möglich, sagte ein Investmentexperte. Es herrschte unvermindert... ► Artikel lesen | |
| NOVAVAX | 5,750 | -0,40 % | Novavax, Inc.: Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights | Total revenue of $70 million in the third quarter of 2025
Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date... ► Artikel lesen | |
| STRYKER | 301,20 | +0,10 % | Intuitive Surgical vs. Stryker: Which MedTech Stock Has More Upside? | ||
| BIOGEN | 147,90 | -0,27 % | Biogen Inc.: The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS | Long-term data published in JAMA Neurology further illustrate the effects of Biogen's QALSODY on function, strength, and survival in SOD1-ALSOver 3 years, a subset of QALSODY-treated participants regained... ► Artikel lesen | |
| ILLUMINA | 115,12 | -0,35 % | MyOme, Inc: Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually | Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 48,400 | +0,83 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112) in Autoimmune Diseases and Hematologic Malignancies | -Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical improvement in patients dosed at the... ► Artikel lesen | |
| CORE ONE LABS | - | - | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 668,00 | +0,33 % | Regeneron Pharmaceuticals: Aktie auf Comeback-Kurs | Die Aktie von Regeneron Pharmaceuticals konnte sich seit unserer positiven Einschätzung Anfang August hervorragend entwickeln und rund 50% Kursgewinn verzeichnen. Trotz Gegenwinds durch auslaufende... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,371 | -0,19 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease | STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA)... ► Artikel lesen | |
| VIKING THERAPEUTICS | 31,070 | +0,58 % | Here is Why H.C. Wainwright Sees Immense Upside for Viking Therapeutics (VKTX) | ||
| EDITAS MEDICINE | 1,857 | +0,19 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen |
FULCRUM THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +1,87 % bei einem Aktienkurs von 12,010 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FULCRUM THERAPEUTICS INC finden Sie auf Wallstreet Online.